Proto-Oncogene Proteins B-raf

"Proto-Oncogene Proteins B-raf" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.

Descriptor ID	D048493
MeSH Number(s)	D08.811.913.696.620.682.700.559.842.374 D12.644.360.400.842.374 D12.776.476.400.842.437 D12.776.624.664.700.204.200
Concept/Terms	Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins B-raf B-raf, Proto-Oncogene Proteins Proteins B-raf, Proto-Oncogene Proto Oncogene Proteins B raf BRAF Kinases B-raf Kinases B raf Kinases Proto-Oncogene Protein B-raf B-raf, Proto-Oncogene Protein Protein B-raf, Proto-Oncogene Proto Oncogene Protein B raf

Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins B-raf".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Serine-Threonine Kinases [D08.811.913.696.620.682.700]
MAP Kinase Kinase Kinases [D08.811.913.696.620.682.700.559]
raf Kinases [D08.811.913.696.620.682.700.559.842]
Proto-Oncogene Proteins B-raf [D08.811.913.696.620.682.700.559.842.374]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intracellular Signaling Peptides and Proteins [D12.644.360]
MAP Kinase Kinase Kinases [D12.644.360.400]
raf Kinases [D12.644.360.400.842]
Proto-Oncogene Proteins B-raf [D12.644.360.400.842.374]
Proteins [D12.776]
Intracellular Signaling Peptides and Proteins [D12.776.476]
MAP Kinase Kinase Kinases [D12.776.476.400]
raf Kinases [D12.776.476.400.842]
Proto-Oncogene Proteins B-raf [D12.776.476.400.842.437]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
raf Kinases [D12.776.624.664.700.204]
Proto-Oncogene Proteins B-raf [D12.776.624.664.700.204.200]

Below are MeSH descriptors whose meaning is related to "Proto-Oncogene Proteins B-raf".

Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins B-raf".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Proto-Oncogene Proteins B-raf" by people in this website by year, and whether "Proto-Oncogene Proteins B-raf" was a major or minor topic of these publications.

Bar chart showing 38 publications over 16 distinct years, with a maximum of 5 publications in 2011 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2009	1	0	1
2011	1	4	5
2012	1	0	1
2013	1	1	2
2014	2	2	4
2015	2	2	4
2016	1	4	5
2017	1	1	2
2018	2	0	2
2019	0	1	1
2020	1	1	2
2021	1	2	3
2022	1	1	2
2023	0	1	1
2026	1	1	2

Below are the most recent publications written about "Proto-Oncogene Proteins B-raf" by people in Profiles.

Wang Y, Belakhoua S, Yang Y, Serrano J, Horbinski C, Boué DR, DeWitt JC, Liechty B, McGuone D, Mao Q, Krasnozhen-Ratush O, Yip S, Dunham C, Umphlett M, Shroff S, Snuderl M. Histopathological and molecular heterogeneity of dysembryoplastic neuroepithelial tumors. J Neuropathol Exp Neurol. 2026 Sep 01; 85(9):1033-1040.

View in: PubMed
Onoyama I, Hardy WR, Takeishi S, Zhu LJ, Tan Y, Hutchinson L, Ou J, Ma L, Virbasius CM, Yasunaga M, Nakayama KI, Shaffer SA, Green MR. Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3. Cancer Sci. 2026 Sep; 117(9):2397-2412.

View in: PubMed
Kim DY, Swetter SM, Huhmann L, Dizon MP, Ferguson JM, Osborne TF, Spence AC, Ziad A, Fillmore N, Hartman RI. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma. J Am Acad Dermatol. 2024 03; 90(3):620-623.

View in: PubMed
Darp R, Vittoria MA, Ganem NJ, Ceol CJ. Oncogenic BRAF induces whole-genome doubling through suppression of cytokinesis. Nat Commun. 2022 07 15; 13(1):4109.

View in: PubMed
Vittoria MA, Kingston N, Kotynkova K, Xia E, Hong R, Huang L, McDonald S, Tilston-Lunel A, Darp R, Campbell JD, Lang D, Xu X, Ceol CJ, Varelas X, Ganem NJ. Inactivation of the Hippo tumor suppressor pathway promotes melanoma. Nat Commun. 2022 06 29; 13(1):3732.

View in: PubMed
Iesato A, Li S, Roti G, Hacker MR, Fischer AH, Nucera C. Lenvatinib Targets PDGFR-? Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights. J Clin Endocrinol Metab. 2021 11 19; 106(12):3569-3590.

View in: PubMed
Khoshkenar P, Lowry E, Mitchell A. Rapid signaling reactivation after targeted BRAF inhibition predicts the proliferation of individual melanoma cells from an isogenic population. Sci Rep. 2021 07 29; 11(1):15473.

View in: PubMed
Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047.

View in: PubMed
Hemond CC, Bakshi R, Tauhid S, Sarrosa R, Ryan M, Kamath V, Thomas J, Edwards KR. Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211033047.

View in: PubMed
Marczynski GT, Laus AC, Dos Reis MB, Reis RM, Vazquez VL. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. Sci Rep. 2020 10 29; 10(1):18682.

View in: PubMed

People

Explore

Similar Concepts

Top Journals